Literature DB >> 22079730

Factors associated with optimal long-term cosmetic results in patients treated with accelerated partial breast irradiation using balloon-based brachytherapy.

Frank A Vicini1, Martin Keisch, Chirag Shah, Sharad Goyal, Atif J Khan, Peter D Beitsch, Maureen Lyden, Bruce G Haffty.   

Abstract

PURPOSE: To evaluate factors associated with optimal cosmetic results at 72 months for early-stage breast cancer patients treated with Mammosite balloon-based accelerated partial breast irradiation (APBI). METHODS AND MATERIALS: A total of 1,440 patients (1,449 cases) with early-stage breast cancer undergoing breast-conserving therapy were treated with balloon-based brachytherapy to deliver APBI (34 Gy in 3.4-Gy fractions). Cosmetic outcome was evaluated at each follow-up visit and dichotomized as excellent/good (E/G) or fair/poor (F/P). Follow-up was evaluated at 36 and 72 months to establish long-term cosmesis, stability of cosmesis, and factors associated with optimal results.
RESULTS: The percentage of evaluable patients with excellent/good (E/G) cosmetic results at 36 months and more than 72 months were 93.3% (n = 708/759) and 90.4% (n = 235/260). Factors associated with optimal cosmetic results at 72 months included: larger skin spacing (p = 0.04) and T1 tumors (p = 0.02). Using multiple regression analysis, the only factors predictive of worse cosmetic outcome at 72 months were smaller skin spacing (odds ratio [OR], 0.89; confidence interval [CI], 0.80-0.99) and tumors greater than 2 cm (OR, 4.96, CI, 1.53-16.07). In all, 227 patients had both a 36-month and a 72-month cosmetic evaluation. The number of patients with E/G cosmetic results decreased only slightly from 93.4% at 3 years to 90.8% (p = 0.13) at 6 years, respectively.
CONCLUSIONS: APBI delivered with balloon-based brachytherapy produced E/G cosmetic results in 90.4% of cases at 6 years. Larger tumors (T2) and smaller skin spacing were found to be the two most important independent predictors of cosmesis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22079730     DOI: 10.1016/j.ijrobp.2011.07.011

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  Brachytherapy in the treatment of breast cancer.

Authors:  Xinna Deng; Haijiang Wu; Fei Gao; Ye Su; Qingxia Li; Shuzhen Liu; Jianhui Cai
Journal:  Int J Clin Oncol       Date:  2017-06-29       Impact factor: 3.402

Review 2.  Accelerated partial breast radiotherapy: a review of the literature and future directions.

Authors:  Nathan R Bennion; Michael Baine; Andrew Granatowicz; Andrew O Wahl
Journal:  Gland Surg       Date:  2018-12

3.  The incidence of fat necrosis in balloon-based breast brachytherapy.

Authors:  Nitesh N Paryani; Laura Vallow; Wilza Magalhaes; Michael G Heckman; Siyong Kim; Ashley Smith; Nancy N Diehl; Sarah McLaughlin
Journal:  J Contemp Brachytherapy       Date:  2015-03-05

Review 4.  Review of advanced catheter technologies in radiation oncology brachytherapy procedures.

Authors:  Jun Zhou; Leonid Zamdborg; Evelyn Sebastian
Journal:  Cancer Manag Res       Date:  2015-07-16       Impact factor: 3.989

5.  Four-year clinical update from a prospective trial of accelerated partial breast intensity-modulated radiotherapy (APBIMRT).

Authors:  Rachel Y Lei; Charles E Leonard; Kathryn T Howell; Phyllis L Henkenberns; Timothy K Johnson; Tracy L Hobart; Shannon P Fryman; Jane M Kercher; Jodi L Widner; Terese Kaske; Dennis L Carter
Journal:  Breast Cancer Res Treat       Date:  2013-07-04       Impact factor: 4.872

6.  Stereotactic Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Rationale, Feasibility, and Early Experience Using the CyberKnife Radiosurgery Delivery Platform.

Authors:  Olusola Obayomi-Davies; Thomas P Kole; Bridget Oppong; Sonali Rudra; Erini V Makariou; Lloyd D Campbell; Hozaifa M Anjum; Sean P Collins; Keith Unger; Shawna Willey; Eleni Tousimis; Brian T Collins
Journal:  Front Oncol       Date:  2016-05-23       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.